Proteasome Inhibition and Allogeneic Hematopoietic Stem Cell Transplantation: A Review

John Koreth, Edwin P. Alyea, William J Murphy, Lisbeth A. Welniak

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


The proteasome and its associated ubiquitin protein modification system have proved to be an important therapeutic target in the treatment of multiple myeloma and other cancers. In addition to direct antitumor effects, proteasome inhibition also exerts strong effects on nonneoplastic immune cells. This indicates that proteasome inhibition, through the use of agents like bortezomib, could be used therapeutically to modulate immune responses. In this review we explore the emerging data, both preclinical and clinical, highlighting the importance of proteasome targeting of immunologic responses, primarily in the context of allogeneic hematopoietic stem cell transplantation (HSCT), both for the control of transplant-related toxicities like acute and chronic graft-versus-host disease (aGVHD, cGHVHD), and for improved malignant disease control after allogeneic HSCT.

Original languageEnglish (US)
Pages (from-to)1502-1512
Number of pages11
JournalBiology of Blood and Marrow Transplantation
Issue number12
StatePublished - Dec 2009


  • Acute GVHD
  • Bortezomib
  • Chronic GVHD
  • Graft-versus tumor
  • NFkb

ASJC Scopus subject areas

  • Transplantation
  • Hematology


Dive into the research topics of 'Proteasome Inhibition and Allogeneic Hematopoietic Stem Cell Transplantation: A Review'. Together they form a unique fingerprint.

Cite this